Anzeige
Mehr »
Login
Freitag, 07.05.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Ad-hoc-Meldung: Ganz großer Hebel freigesetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 766093 ISIN: US7665596034 Ticker-Symbol: RI2A 
Tradegate
06.05.21
16:52 Uhr
2,734 Euro
-0,153
-5,30 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
RIGEL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
RIGEL PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,7002,75406.05.
2,6572,77306.05.

Aktuelle News zur RIGEL PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
RIGEL PHARMACEUTICALS Aktie jetzt für 0€ handeln
DoRigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q1 2021 Results - Earnings Call Transcript2
DoRigel Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation2
MiRigel Pharmaceuticals Inc. Bottom Line Rises In Q1164WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals Inc. (RIGL) revealed a profit for its first quarter that rose from the same period last year.The company's earnings totaled $39.50 million, or $0.22...
► Artikel lesen
MiRIGEL PHARMACEUTICALS INC - 10-Q, Quaterly Report-
MiRIGEL PHARMACEUTICALS INC - 8-K, Current Report1
23.04.Rigel Pharmaceuticals: Escalating Value Drivers Improve Upside Potential6
13.04.RIGEL PHARMACEUTICALS INC - 8-K, Current Report4
13.04.Why Rigel Pharmaceuticals Stock Jumped Today6
13.04.Rigel Pharma shares surge as fostamatinib meets primary endpoint of safety in COVID-196
13.04.Rigel Pharma Says Phase 2 Trial Of Fostamatinib For COVID-19 Met Primary Endpoint Of Safety275WASHINGTON (dpa-AFX) - Biotechnology company Rigel Pharmaceuticals, Inc. (RIGL) announced Tuesday positive topline results from a multi-center, Phase 2 clinical trial to evaluate the safety...
► Artikel lesen
07.04.Rigel Pharmaceuticals calls off R552 licensing agreement with Eli Lilly5
11.03.Rigel Completes Patient Enrollment In Phase 2 Trial To Evaluate Fostamatinib In COVID-19 Patients237WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) announced the completion of patient enrollment in a multi-center phase 2 clinical trial to evaluate the safety of fostamatinib, the...
► Artikel lesen
03.03.Rigel Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation8
03.03.Rigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q4 2020 Results - Earnings Call Transcript7
02.03.EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q4 Earnings Report1.010WASHINGTON (dpa-AFX) - Below are the earnings highlights for Rigel Pharmaceuticals Inc. (RIGL):-Earnings: -$19.24 million in Q4 vs. -$17.20 million in the same period last year. -EPS: -$0.11...
► Artikel lesen
02.03.Rigel Pharmaceuticals EPS in-line, beats on revenue4
02.03.RIGEL PHARMACEUTICALS INC - 8-K, Current Report2
19.02.FLXN On Track, IMNM Discovers Antibodies To Fight S. African Variant, RIGL In Deal With Eli Lilly2.660INDIANAPOLIS (dpa-AFX) - Today's Daily Dose brings you news about the progress in Flexion Therapeutics' pipeline; Immunome's coronavirus research program; Pfizer/BioNTech testing COVID-19...
► Artikel lesen
18.02.RIGL Stock: Why Rigel Pharmaceuticals Is Climbing Today6
18.02.Lilly, Rigel Enter Exclusive CNS Development Collaboration3
Seite:  Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1